Cytokeratin and CD30 expression in dysgerminoma

被引:18
|
作者
Cossu-Rocca, Paolo
Jones, Timothy D.
Roth, Lawrence M.
Eble, John N.
Zheng, Wenxin
Karim, Fadi W. Abdul
Cheng, Liang
机构
[1] Indiana Univ, Med Ctr, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA
[2] Univ Sassari, Dipartimento Patol, I-07100 Sassari, Italy
[3] Yale Univ, Dept Pathol, New Haven, CT 06520 USA
[4] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
关键词
ovarian neoplasia; germ cell tumors; dysgerminoma; immunohistochemistry; E-cadherin; CD30; histogenesis;
D O I
10.1016/j.humpath.2006.02.018
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Dysgerminoma is a malignant germ cell tumor of the ovary that shares morphological, immunophenotypic, and genetic features with its testicular counterpart, seminoma. Recent evidence supports the hypothesis that seminoma can differentiate into non-seminomatous germ cell tumor types. The progression of these tumors can be measured by their acquisition of the potential to express cytokeratin intermediate filaments, a characteristic specific to epithelial differentiation. Although testicular seminomas have been widely investigated, little is known about cytokeratin or E-cadherin expression in dysgerminomas. We investigated 26 formalin-fixed, paraffin-embedded ovarian dysgenninomas with immunohistochemical stains for CAM5.2, AE1/AE3, epithelial membrane antigen, cytokeratin 7, cytokeratin 20, high-molecular-weight keratin, and E-cadherin. In addition, we investigated the CD30 and vimentin immunoreactivity of these tumors. Immunoreactivity for CAM5.2 and for AE1/AE3 was present in more than 10% of neoplastic cells in 5 (19.2%) of 26 cases and in 2 (7.7%) of 26 cases, respectively. Cytokeratin 7 showed only focal positivity and never showed positive staining in greater than 10% of dysgerminoma cells. E-cadherin staining was positive in 2 cases showing weak membranous immunostaining in more than 10% of cells. Vimentin immunoreactivity was observed in only 2 dysgerminomas, both of which had less than 10% of the neoplastic cells staining. Cytokeratin 20, epithelial membrane antigen, high-molecular-weight keratin, and CD30 were consistently negative in all cases. Our study demonstrates that cytokeratin expression in dysgerminomas is not unusual and is consistent with the hypothesis that dysgerminomas have the capacity to differentiate along epithelial lines. Furthermore, the immunohistochemical staining patterns for cytokeratins, E-cadherin, and CD30 in dysgerminomas need to be considered when assessing differential diagnoses in difficult cases of primary ovarian tumors. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1015 / 1021
页数:7
相关论文
共 50 条
  • [21] A review of CD30 expression in cutaneous neoplasms
    Kampa, Franziska
    Mitteldorf, Christina
    JOURNAL OF CUTANEOUS PATHOLOGY, 2021, 48 (04) : 495 - 510
  • [22] CD30 ligand in lymphoma patients with CD30(+) tumors
    Younes, A
    Consoli, U
    Snell, V
    Clodi, K
    Kliche, KO
    Palmer, JL
    Gruss, HJ
    Armitage, R
    Thomas, EK
    Cabanillas, F
    Andreeff, M
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (11) : 3355 - 3362
  • [23] CD30:CD30 ligand interactions in the immune response
    Opat, S
    Gaston, JSH
    AUTOIMMUNITY, 2001, 33 (01) : 45 - 60
  • [24] Crosslinking of CD30 on activated human Th clones enhances their cytokine production and downregulates the CD30 expression
    Bengtsson, Å
    Scheynius, A
    Avila-Cariño, J
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2000, 52 (06) : 595 - 601
  • [25] EXPRESSION AND REGULATION OF CD30 LIGAND AND CD30 IN HUMAN LEUKEMIA-LYMPHOMA CELL-LINES
    GRUSS, HJ
    DASILVA, N
    HU, ZB
    UPHOFF, CC
    GOODWIN, RG
    DREXLER, HG
    LEUKEMIA, 1994, 8 (12) : 2083 - 2094
  • [26] EXPRESSION AND MODULATION OF CD30 LIGAND AND CD30 IN 102 HUMAN LEUKEMIA-LYMPHOMA CELL-LINES
    GRUSS, HJ
    DASILVA, N
    HU, ZB
    MA, W
    UPHOFF, CC
    GOODWIN, RG
    DREXLER, HG
    BLOOD, 1993, 82 (10) : A482 - A482
  • [27] CD30 Expression in Patients with Chronic Myelomonocytic Leukemia
    Al-Kali, Aref
    Greipp, Patricia
    Patnaik, Mrinal M.
    Gangat, Naseema
    Begna, Kebede H.
    Alkhateeb, Hassan B.
    Elliott, Michelle A.
    Hogan, William J.
    Litzow, Mark R.
    Phuong Nguyen
    He, Rong
    BLOOD, 2017, 130
  • [28] CD30 EXPRESSION IN NON-HODGKINS-LYMPHOMA
    PIRIS, M
    BROWN, DC
    GATTER, KC
    MASON, DY
    HISTOPATHOLOGY, 1990, 17 (03) : 211 - 218
  • [29] CD30 expression and apoptosis in human blood eosinophils
    Berro, AI
    Agrawal, DK
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S229 - S229
  • [30] Aberrante CD30 Expression in cutaneous Manifestations of Mastocytosis
    Kulberg, A.
    Tronnier, M.
    Mitteldorf, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 6 - 6